FY2024 Earnings Estimate for AXDX Issued By William Blair

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) – Equities researchers at William Blair decreased their FY2024 earnings per share estimates for shares of Accelerate Diagnostics in a research note issued to investors on Monday, November 11th. William Blair analyst A. Brackmann now anticipates that the medical research company will post earnings per share of ($2.30) for the year, down from their previous estimate of ($2.14). The consensus estimate for Accelerate Diagnostics’ current full-year earnings is ($2.14) per share. William Blair also issued estimates for Accelerate Diagnostics’ Q4 2024 earnings at ($0.50) EPS, Q1 2025 earnings at ($0.49) EPS, Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS and FY2025 earnings at ($2.00) EPS.

Separately, StockNews.com raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Thursday.

Accelerate Diagnostics Trading Down 3.6 %

Shares of NASDAQ AXDX opened at $1.89 on Thursday. The stock has a fifty day moving average price of $1.77 and a 200 day moving average price of $1.46. The company has a market cap of $47.33 million, a P/E ratio of -0.66 and a beta of 0.59. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $5.78.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Accelerate Diagnostics stock. Griffin Asset Management Inc. increased its stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 1.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,380,654 shares of the medical research company’s stock after purchasing an additional 26,400 shares during the quarter. Griffin Asset Management Inc. owned about 6.26% of Accelerate Diagnostics worth $1,615,000 at the end of the most recent quarter. 17.14% of the stock is currently owned by hedge funds and other institutional investors.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.